Disease Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
0.010 GeneticVariation BEFREE The third-generation tyrosine kinase inhibitor (TKI) ponatinib shows activity against all common BCR-ABL1 single mutants, including the highly resistant BCR-ABL1-T315I mutant, improving outcome for patients with refractory chronic myeloid leukemia (CML). 26773037 2016